Profile data is unavailable for this security.
About the company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-17.46m
- Incorporated2017
- Employees3.00
- LocationCNS Pharmaceuticals Inc2100 West Loop S Ste 900HOUSTON 77027-3522United StatesUSA
- Websitehttps://cnspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aditxt Inc | 506.45k | -41.45m | 2.69m | 47.00 | -- | 0.2264 | -- | 5.31 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Novelstem International Corp | 15.00k | -4.22m | 2.81m | 15.00 | -- | -- | -- | 187.53 | -0.09 | -0.09 | 0.0003 | -0.0478 | 0.0065 | -- | 10.00 | -- | -172.16 | -- | -1,011.77 | -- | -- | -- | -26,418.53 | -- | -- | -8.40 | 2.34 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -11.33m | 2.90m | 4.00 | -- | -- | -- | -- | -2.16 | -2.22 | 0.00 | -0.5417 | 0.00 | -- | -- | 0.00 | -133.27 | -- | -800.31 | -- | -- | -- | -- | -- | -- | -4.14 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -13.96m | 2.93m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 2.94m | 21.00 | -- | 0.2953 | -- | 0.6265 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -16.28m | 2.99m | 18.00 | -- | 0.1569 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Alzamend Neuro Inc | 0.00 | -12.40m | 3.04m | 4.00 | -- | -- | -- | -- | -18.70 | -18.70 | 0.00 | -5.72 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 3.07m | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 3.07m | 5.00 | -- | 1.11 | -- | 6.44 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -406.65k | 3.09m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 3.11m | 1.00 | -- | 1.46 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | 0.00 | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.17m | 40.00 | -- | 0.0454 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -105.53m | 3.21m | 7.00 | -- | 0.2864 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
| Virax Biolabs Group Ltd | 0.00 | -1.71m | 3.24m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
| Ensysce Biosciences Inc | 1.75m | -11.55m | 3.25m | 7.00 | -- | 0.8365 | -- | 1.86 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| GB Sciences Inc | 0.00 | -4.03m | 3.35m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
Data as of Jul 26 2024. Currency figures normalised to CNS Pharmaceuticals Inc's reporting currency: US Dollar USD
7.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 9.42k | 3.97% |
| Virtu Americas LLCas of 31 Mar 2024 | 1.89k | 0.80% |
| Citadel Securities LLCas of 31 Mar 2024 | 1.82k | 0.77% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.17k | 0.49% |
| Geode Capital Management LLCas of 31 Mar 2024 | 565.00 | 0.24% |
| Jane Street Capital LLCas of 31 Mar 2024 | 548.00 | 0.23% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 451.00 | 0.19% |
| HRT Financial LLCas of 31 Mar 2024 | 438.00 | 0.19% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 436.00 | 0.18% |
| XTX Markets LLCas of 31 Mar 2024 | 375.00 | 0.16% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
